Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Simple Blood Test Can Detect Breast and Ovarian Cancer Risk without Genetic Sequencing

By LabMedica International staff writers
Posted on 12 Jun 2023

The BRCA1 and BRCA2 genes, critical for DNA repair, can sometimes mutate and cause an increased risk for certain types of cancer, including breast, ovarian, pancreatic, and prostate cancer. In the US, those with a family history of these cancers may be advised to undergo genetic testing for mutations in these genes. If found positive, they could opt for additional screening or surgery to mitigate their risk. However, in the US, only 10% out of the estimated one million presumed carriers of BRCA1/2 mutations are aware of their status. Furthermore, in India, BRCA mutation tests are not widely accessible. A more efficient detection method could potentially allow many more individuals to become aware of their inherited high cancer risk.

Researchers from Dana-Farber Cancer Institute (Boston, MA, USA) and their collaborators have discovered an alternative method to identify increased cancer risk associated with BRCA1 and BRCA2 mutations, which doesn't involve genetic sequencing. Instead of searching for BRCA1/2 gene mutations, the assessment focuses on functional changes that take place when the pathway regulated by these genes is impaired. This innovative risk-detection technique could lay the groundwork for a more accessible, affordable, and potentially more comprehensive method of identifying an inherited risk for breast or ovarian cancer.

The researchers were able to identify increased risk via the presence of a specific group of microRNAs in the blood. MicroRNAs, short, non-coding, hairpin-shaped RNA molecules that circulate in our blood, are emerging as powerful disease biomarkers. The presence of a certain group of microRNAs indicates an active breakdown in the DNA repair process, similar to the distinctive knocking sound from a malfunctioning car engine. Conversely, the absence of this group suggests a working DNA repair process, as smooth as a purring engine.

In the proof-of-concept study, the researchers analyzed blood samples from 653 individuals sourced from six biorepositories located in the US, Poland, and India. Approximately half of the samples tested positive for BRCA mutations. Utilizing next-generation sequencing, the team identified the microRNAs in each sample and created a data set containing the microRNAs and BRCA mutation status for each sample. By applying machine learning, they were able to identify a unique microRNA pattern exclusively present in the samples positive for BRCA mutations. Their model correctly identified the presence of BRCA mutations 94% of the time, confirming this approach as a novel method to identify increased cancer risk.

While this proof-of-concept study does not form the foundation for a clinical test that could be included in an annual exam, it does hint at the feasibility of an affordable clinical test. PCR tests, such as those used for detecting COVID-19, could replace next-generation sequencing to detect the microRNA signature, thereby making it affordable and accessible. The researchers believe such as test could provide a more comprehensive risk assessment compared to genetic sequencing of the BRCA1 and BRCA2 genes, as it captures active signs of pathology, irrespective of the gene mutations causing it. Currently, genetic testing only detects known defects in a few specific genes that might disrupt the DNA repair process.

“What if we had an accessible and affordable test for inherited cancer risk that you can get done as an annual physical, the same way we test for diabetes or heart disease risk?” said senior author and Dana-Farber researcher Dipanjan Chowdhury, PhD. “These study results suggest that such a test is in the realm of possibility.”

Related Links:
Dana-Farber Cancer Institute

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.